Second Phase 3 clinical trial again shows dupilumab lessens disease in COPD patients with type 2 inflammation
BIRMINGHAM, Ala. – Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed...